Introduction {#s0001}
============

*Rheum undulatum* Linne (Polygonaceae) is a traditional herbal medicine in East Asian countries used for haematemesis, melena, and menorrhagia (Matsuda et al. [@CIT0021]). The reported pharmacological effects of *R. undunalum* include improving movement of the colon, liver protection, antibacterial, anti-inflammatory, and anti-aging effects. Components of *R. undulatum* include rhein, emodin, aloe-emodin, sennoside A, chrysophanol, and resveratrol (Lee et al. [@CIT0017]; Yoo et al. [@CIT0041]). Although emodin is present in several plants including those of the genera *Aloe and Cassia, Rheum undulatum* is a representative plant having emodin as an active component in traditional oriental medicine. Emodin has been shown to have various effects (Chen et al. [@CIT0003]; Xue et al. [@CIT0040]; Pang et al. [@CIT0026]). However, its effects on liver damage are not fully understood and its mechanisms have not been clearly investigated.

Oxidative stress, which is a major cause of various liver diseases (Li et al. [@CIT0018]), is defined as break-down of the physiological balance between reactive oxygen species (ROS) and the body efficacy of ROS removal (Gupta et al. [@CIT0013]). ROS and inflammatory cytokines promote activation of phospholipases, and phospholipase A~2~ (PLA~2~) stimulates the release of arachidonic acid (AA) (Gijón et al. [@CIT0012]; Shin and Kim [@CIT0031]). Liberated AA serves as a substrate of oxidation by the action of cyclooxygenase (COX) to generate eicsanoids. AA mediates oxidative stress, DNA damage, protein oxidation, inflammatory responses, and cell death (Kim et al. [@CIT0015]).

Iron is an essential transition metal that maintains oxygen utilization in our bodies. The majority of iron in humans is stored in the liver, spleen and bone marrow (Purohit and Brenner [@CIT0027]). However, when excess iron exists, it may result in inflammatory conditions and cause higher release of AA, enhancing oxidative stress (Shin and Kim [@CIT0031]). Therefore, a combination of AA and iron is used as an oxidative stress inducer in many studies because of its synergistic toxicity, in which iron might play a role as a catalyst of oxidation (Caro and Cederbaum [@CIT0001]; Shin and Kim [@CIT0031]; Dong et al. [@CIT0008]; Choi et al. [@CIT0005]).

Various types of signalling might be involved in the pathological process of oxidative stress in the cells. AMPK is a heterotrimer kinase complex consisting of α, β and γ subunits (Horie et al. [@CIT0014]) that play a critical role in energy homeostasis by responding to low cellular energy (Emerling et al. [@CIT0009]). Co-treatment with AA and iron is known to produce increased oxidative stress, which were successfully inhibited by some beneficial compounds including oltipraz, isorhamnetin, isoliquiritigenin, sauchinone and metformin via AMP-activated protein kinase (AMPK)-related pathway oxidation (Caro and Cederbaum [@CIT0001]; Shin and Kim [@CIT0031]; Dong et al. [@CIT0008]; Choi et al. [@CIT0005]).

Therefore, we verified the protective effects of emodin against oxidative stress induced by AA + iron in hepatocyte. We found that emodin exerts hepatocyte protective effects against AA + iron induced oxidative stress. Emodin was also applied in acetaminophen (paracetamol, APAP)-induced acute liver damage model, the representative model of oxidative stress *in vivo*. In mice, emodin attenuated hepatocyte damage and the dysregulation of antioxidant enzyme in the tissue sample. Moreover, we found that emodin regulated AMPK and Hippo signalling, which are closely related to oxidative stress (Wada et al. [@CIT0034]; Xiao et al. [@CIT0039], Morinaka et al. [@CIT0023]), suggesting that these signalling pathways influence the effects of emodin in the liver, as indicated by next generation sequencing (NGS), immunoblot and immunohistochemical analysis.

Materials and methods {#s0002}
=====================

Reagents {#s0003}
--------

Emodin, dimethylsulphoxide (DMSO), ferric nitrate, nitrilotriacetic acid, 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl-tetrazolium bromide (MTT), rhodamine 123 (Rh123), 2′,7′-dichlorofluorescein diacetate (DCFH-DA) were purchased from Sigma (St. Louis, MO, USA). Anti-PARP, anti-procaspase-3, anti-Bcl-xL, anti-phospho-acetyl-CoA carboxylase (ACC), anti-AMPKα, anti-phospho-AMPKα, anti-LKB1, anti-phospho-LKB1, anti-Yes-associated protein (YAP), and anti-phospho-YAP antibodies were obtained from Cell Signalling Technology (Beverly, MA, USA).

Cell culture {#s0004}
------------

HepG2, SK-Hep-1, Huh-7 and HeLa cells were obtained from ATCC (Rockville, MD, USA) (Dong et al. [@CIT0008]). HepG2 cells were cultured in Eagle's minimum essential medium (DMEM) low glucose with 10% FBS and 10 mg/mL normocin. SK-Hep-1, Huh-7 and HeLa cells were cultured in Eagle's minimum essential medium (DMEM) high glucose with 10% FBS, 50 units/mL penicillin and 50 μg/mL streptomycin.

Cell viability assay {#s0005}
--------------------

For MTT assay, HepG2 cells were plated and grown to 80--90% confluency and incubated with serum free media for 12 h followed by emodin for 1 h prior to AA treatment for 12 h followed by iron for 2 h (Dong et al. [@CIT0008]; Choi et al. [@CIT0005]). For lactate dehydrogenase (LDH) assay, HepG2 cells were plated in 96-well plate and treated as described in MTT assay. LDH assay was performed by CytoTox 96^®^ assay kit (Promega, Madison, WI, USA) as assigned protocols.

Reactive oxygen species (ROS) production {#s0006}
----------------------------------------

DCFH-DA was used to measure intracellular ROS production in HepG2 cells (Choi et al. [@CIT0005]). Cells were incubated with 10 μM DCFH-DA for 1 h, and fluorescence was detected by ELISA microplate reader.

RNA extraction {#s0007}
--------------

Total RNA was individually extracted using Trizol following the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA) (Dong et al. [@CIT0008]; Choi et al. [@CIT0005]).

Library preparation and QuantSeq (RNA-seq) {#s0008}
------------------------------------------

The library was constructed using QuantSeq 3′ mRNA-Seq Library Prep Kit (Lexogen, Inc., Austria) according to the manufacturer's instructions. Samples were prepared with total RNA of 500 ng. Following that an oligo-dT primer containing an Illumina-compatible sequence on its 5′ end was hybridized to the RNA, reverse transcription was performed. The RNA templates were removed, and second strand synthesis was performed by a random primer containing an Illumina-compatible linker sequence on its 5′ end. The double-stranded library was purified using magnetic beads. The library was amplified to add the complete adapter sequences required for cluster generation, and the purification process was done to remove from PCR components. The final library was sequenced using NextSeq 500 (Illumina, Inc., USA) at Ebiogen Inc (Seoul, South Korea) to generate 75pb single-end sequences.

NGS data analysis {#s0009}
-----------------

QuantSeq 3′ mRNA-Seq reads were aligned using Bowtie2 (Langmead and Salzberg [@CIT0016]). The alignment files were used to assemble transcripts, to estimate the relative abundances and to detect differential expression of genes. Differentially expressed genes were determined based on the counts from unique and multiple alignments using Bedtools (Quinlan and Hall [@CIT0028]). The read count data were processed based on Quantile normalization method using EdgeR implemented in R Bioconductor (Gentleman et al. [@CIT0011]). Gene classification was based on the searches in DAVID (<http://david.abcc.ncifcrf.gov/>) and Medline databases (<http://www.ncbi.nlm.nih.gov/>).

Mitochondrial membrane potential (MMP) measurement {#s0010}
--------------------------------------------------

HepG2 cells were plated in 6-well plates and treated with emodin, AA and iron as described (Dong et al. [@CIT0008]; Choi et al. [@CIT0005]). MMP was measured by FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA. USA).

Immunoblot analysis {#s0011}
-------------------

Treated cells were lysed in RIPA buffer at 4 °C and lysates were collected. The membrane was developed using ECL (Advensta, Menlo Park, CA, USA) and a gel-doc image analyser (Vilber Lourmat, France) (Dong et al. [@CIT0008]; Choi et al. [@CIT0005]).

Animals and treatment {#s0012}
---------------------

Male C57B/6 mice (5 weeks old, 18 g) were purchased from Charles River Orient Bio (Seongnam, Korea). All *in vivo* experiment procedures were approved by the Institutional Animal Care and Use Committee of the Daegu Haany University, and were conducted in agreement with the guidelines of the National Institutes of Health. Emodin was dissolved in 40% polyethylene glycol (PEG) and orally injected for three consecutive days (10 and 30 mg/kg) (Ding et al., [@CIT0007]). After last injection of emodin, mice were fasted for 16 h and 500 mg/kg APAP was orally injected. All mice were sacrificed 6 h after APAP injection, and blood and liver sample were collected (Ganey et al., [@CIT0010]). Control group was also treated with 40% PEG.

Haematoxylin and eosin staining {#s0013}
-------------------------------

Tissue block was sectioned in 4 μm thick ribbon and applied on slide glass. After deparaffinization in xylene, tissue sections were hydrated in EtOH and stained in haematoxylin for 5 min. After blueing, tissue sections were stained with eosin for 10 sec. Followed by eosin, tissue sections were dehydrated and cleared before mounting.

Statistical analysis {#s0014}
--------------------

One-way analysis of variance procedures was used to assess significant differences among treatment groups. The criterion for statistical significance was set at *p* \< 0.05 or *p* \< 0.01.

Results {#s0015}
=======

Inhibition of cell death {#s0016}
------------------------

First, we determined the effects of emodin on cell viability and found that there was no cytotoxicity of emodin in response to concentrations up to 30 μM (data not shown) in HepG2 cells. Next, increasing doses (3, 10, 30 μM) of emodin were applied to investigate the cell protective effect against AA + iron-induced oxidative stress in HepG2 cells. Cell viability was assessed by MTT assay and LDH assay. In the MTT assay, AA + iron treatment decreased cell viability to 28.9% of the control. Emodin treatment of 10 μM and 30 μM attenuated AA + iron induced cytotoxicity ([Figure 1(A)](#F0001){ref-type="fig"}). In the LDH assay, AA + iron elevated LDH release up to 6.8-fold compared to control. However, emodin treatment abrogated LDH release induced by these toxicants ([Figure 1(B)](#F0001){ref-type="fig"}). In addition, exposure of cells to AA + iron treatment caused cleavage of caspase-3 ([Figure 1(C)](#F0001){ref-type="fig"}).

![Inhibition of AA + iron induced cell death by emodin. (A) MTT assay and (B) LDH assay. HepG2 cells were incubated with multiple doses (3, 10, 30 μM) of emodin (Emo) 1 h prior to 10 μM AA treatment. After 12 h, cells were incubated with 5 μM iron for 2h. (C) Western blot analysis of apoptosis related proteins was performed with HepG2 cell lysates. HepG2 cells were incubated with AA + iron as describe in panel A with or without 30 μM Emo. All data represent means ± SD of three independent experiments (*\*\*p *\< 0.01 between control and AA + iron treated cells; *\#\#p *\< 0.01, *\#p*\< 0.05 between AA + iron treated cells with or without Emo). AA: arachidonic acid; Emo: emodin.](IPHB_A_1750658_F0001_B){#F0001}

Prevention of ROS production and mitochondrial dysfunction {#s0017}
----------------------------------------------------------

To investigate the anti-oxidant effects of emodin, we measured intracellular ROS using a spectrophotometer. Although 30 μM emodin alone did not cause intracellular ROS production, the AA + iron-treated group showed 6.68-fold increased ROS compared to the control. However, treatment with emodin completely inhibited elevation of ROS production by AA + iron in HepG2 cells ([Figure 2(A)](#F0002){ref-type="fig"}). To examine whether emodin exerts cytoprotective effects via mitochondrial protection, we measured mitochondrial membrane permeability (MMP) by using FACS with Rh123 staining in HepG2 cells. In the AA + iron-treated group, we observed left shift of histogram, which was significantly inhibited by treatment of 30 μM emodin as assessed by FACS analysis ([Figure 2(B)](#F0002){ref-type="fig"}). Based on the M1 population, we determined the fold change of the RN1 fraction. The AA + iron treated group showed 6.1-fold more Rh123 positive cells than the control group, and emodin treatment successfully prevented increasing Rh123 positive cells ([Figure 2(B)](#F0002){ref-type="fig"}).

![Effect of emodin on AA + iron-induced mitochondrial dysfunction and oxidative stress. (A) Intracellular ROS production measurement by DCF-DA. HepG2 cells were incubated as describe in [Figure 1C](#F0001){ref-type="fig"}. (B) Detection of mitochondrial membrane permeability (MMP) change by FACS analysis. RN1 fraction (Low rh123 staining cell population) was expressed as fold change in the graph. All data represent means ± SD of three independent experiments (*\*\*p *\< 0.01 between control and AA + iron treated cells; *\#\#p *\< 0.01, *\#p*\< 0.05 between AA + iron treated cells with or without Emo). AA: arachidonic acid; Emo: emodin; MMP: mitochondrial membrane permeability.](IPHB_A_1750658_F0002_B){#F0002}

LKB1-mediated AMPKα activation {#s0018}
------------------------------

We assessed the effects of emodin in AMPK activation. The useful marker of AMPK activation, phosphorylation of ACC, was observed in HepG2 ([Figure 3(A)](#F0003){ref-type="fig"}), SK-Hep-1 ([Figure 3(B)](#F0003){ref-type="fig"}) and Huh-7 cells ([Figure 3(C)](#F0003){ref-type="fig"}). In HepG2 cells, the maximum activation of AMPKα was observed after 10 min of incubation with 30 μM emodin treatment, while peak values were observed after 30 min for Huh-7 cells and 3 h for SK-Hep-1 cells. To verify whether AMPK activation is mediated by its major upstream target, LKB1, 30 μM emodin was applied to HepG2 cells ([Figure 3(D)](#F0003){ref-type="fig"}). We found phosphorylation of LKB1 after 10 mins of emodin incubation for HepG2 cells. Furthermore, there was no activation of AMPKα in HeLa cells, which are LKB1 deficient cells ([Figure 3(E)](#F0003){ref-type="fig"}). To confirm a critical role of AMPKα activation in hepatocyte viability, we conducted a MTT assay of HeLa and HepG2 cells. As expected, emodin failed to protect oxidative stress induced cell death ([Figure 4(A)](#F0004){ref-type="fig"}). In addition, treatment with compound C (an AMPK inhibitor) significantly prevented the cell protective effect of emodin ([Figure 4(B)](#F0004){ref-type="fig"}).

![AMPKα activation by emodin. HepG2 cells were incubated in serum free media for 12 h, and then treated with 30 μM Emo for indicated time periods. Western blotting analysis of p-ACC, p-AMPKα and β-actin and band intensity of p-ACC (*\*\*p* \< 0.01 between vehicle and Emo-treated cells). Western blotting analysis was performed with HepG2 (A), SK-Hep-1 (B) and Huh-7 cells (C). (D) Expression of p-LKB1 in HepG2 cells. (E) Compare of LKB1-deficient Hela cells and HepG2 cells. Emo: emodin.](IPHB_A_1750658_F0003_B){#F0003}

![AMPKα and YAP co-relation mediated hepatocyte protective effect of emodin. (A) MTT assay of HeLa and HepG2 cells. HepG2 cells were incubated as describe in [Figure 1C](#F0001){ref-type="fig"}. (B) Reversed cell viability by compound C (a chemical inhibitor of AMPK) in HepG2 cells. HeLa cells or HepG2 cells were treated with 10 μM compound C for 30 min and incubated with 10 μM Emo for 1 h, continuously incubated with 10 μM AA for 12 h, and exposed to 5 μM iron for 2 h. All data represent means ± SD of three independent experiments (*\*\*p* \< 0.01 between control and AA + iron treated cells; *\#\#p* \< 0.01, *\#p*\< 0.05 between AA + iron treated cells with or without Emo). (C) Expression of p-LATS1, p-YAP and YAP in HepG2 cells. Hela cells or HepG2 cells were incubated in serum free media for 12 h and treated with 30 μM Emo for indicated time periods. (D) Compare of HeLa cells and HepG2 cells in expression of p-YAP. Com.C: compound C; Emo: emodin.](IPHB_A_1750658_F0004_B){#F0004}

Yap inactivation {#s0019}
----------------

Recent findings also showed that the Hippo pathway could be related with oxidative stress (Morinaka et al. [@CIT0023]; Wada et al. [@CIT0034]; Xiao et al. [@CIT0039]). YAP1 is one of the key downstream targets suppressed by the Hippo pathway, and a transcription activator that mediates ROS-triggered signalling. Therefore, we next investigated the effects of emodin in the Hippo signalling pathway related proteins, LATS1 and YAP. In the HepG2 cells, emodin induced the phosphorylation of LATS1 and YAP, and the peak was around 3 h after treatment ([Figure 4(C)](#F0004){ref-type="fig"}). Emodin was applied to HeLa cells to verify the relationship of AMPKα and YAP activation and LKB1 deficient cells showed no change in p-YAP expression in response to emodin stimulation ([Figure 4(D)](#F0004){ref-type="fig"}).

Liver protection in mice {#s0020}
------------------------

AMPK activation by emodin was confirmed *in vivo*. Oral treatments of 10 and 30 mg/kg emodin successfully induced phosphorylation of AMPK and ACC in liver of mice ([Figure 5(A)](#F0005){ref-type="fig"}). Next, the oral administration of 10 and 30 mg/kg emodin was assessed to protect the liver. In a mouse model study, APAP was used to induce liver toxicity. The histological analysis revealed that the emodin pre-treated group underwent lower damage of sinusoidal space arrangement and nuclear morphological changes as well as the more arranged patterns of hepatocyte induced by APAP treatment ([Figure 5(B)](#F0005){ref-type="fig"}). Oral administration of emodin also decreased the APAP-induced ALT and AST levels, which are biological markers of liver tissue damage (data not shown). Moreover, the immunoblot assessments revealed that emodin markedly recovered the dysregulation of antioxidant enzyme (i.e., glutathione peroxidase) and its related signalling induced by APAP ([Figure 5(C)](#F0005){ref-type="fig"}).

![Effect of emodin on acetaminophen (APAP)-induced liver injury in mice. (A) Western blot analysis of p-AMPK and p-ACC. (B) H&E staining. Microscopic images of liver showed hepato-protective effect of Emo against APAP-induced liver damage. APAP-induced serum ALT and AST level was decreased by Emo. Mice were treated with 10 and 30 mg/kg Emo for three consecutive days, followed by 16 h of starvation. Then, mice were orally administrated with 500 mg/kg APAP. (C) Representative immunoblots of glutathione peroxidase (GPx) and p-LATS1. Arrows indicate degeneration of hepatocytes. Bar = 50 μm. APAP: acetaminophen; Emo: emodin; GPx: glutathione peroxidase.](IPHB_A_1750658_F0005_C){#F0005}

Differentially expressed genes (DEGs) in RNA-seq analysis data {#s0021}
--------------------------------------------------------------

We conducted quantitative RNA-seq analysis using RNA samples from control and 10 mg/kg emodin treated mice liver tissues and attempted to compare gene expression profiles between them to identify target genes and related pathways that might be responsible for the regulation of these genes. Genes differentially regulated by more than 10-fold in the emodin injected group compared to the control group were found and listed in [Supplementary Table 1](https://doi.org/10.1080/13880209.2020.1750658). Comparison of the gene expression profiles identified 416 genes for which expression levels (fold change \> 2 and *p*-value \< 0.05) were changed after emodin treatment. These genes were likely involved in the KEGG pathway (61 genes), chemokine signalling pathway (14 genes), cytokine-cytokine receptor interaction (13 genes), MAPK signalling pathway (10 genes), PI3K-Akt signalling pathway (13 genes) and TNF signalling pathway (11 genes; [Table 1](#t0001){ref-type="table"}).

###### 

KEGG pathway analysis for differentially expressed genes (DEGs).

  KEGG pathway                             *p* Value   DEGs counts
  ---------------------------------------- ----------- -------------
  Chemokine signalling pathway             6.5E − 5    14
  Cytokine-cytokine receptor interaction   1.9E − 3    13
  MAPK signalling pathway                  4.5E − 2    10
  PI3K-Akt signalling pathway              2.9E − 2    13
  TNF signalling pthway                    3.1E − 5    11

Several of the most strongly induced genes were targets of the AMPK signalling pathway and the Hippo pathway ([Figure 6(A)](#F0006){ref-type="fig"}; [Tables 2](#t0002){ref-type="table"} and [3](#t0003){ref-type="table"}). Prkaa1 (5′-AMP-activated protein kinase catalytic subunit α-1) was significantly upregulated (1.25-fold), while Prkaa2 (5′-AMP-activated protein kinase catalytic subunit α-2) and Prkab1 (5′-AMP-activated protein kinase subunit β-1) were significantly downregulated (0.08-fold: Prkaa2, 0.78-fold: Prkab1) in response to emodin when compared with the control ([Figure 6(A)](#F0006){ref-type="fig"}; [Table 2](#t0002){ref-type="table"}). The commonly known YAP target genes, Lats1 (Large Tumour Suppressor Kinase 1) and Mob1b (MOB Kinase Activator 1B), showed a striking level of upregulation (1.15-fold: Lats1, 1.36-fold: Mob1b; [Figure 6(B)](#F0006){ref-type="fig"}; [Table 2](#t0002){ref-type="table"}). However, Ajuba, a negative regulator of the Hippo signalling pathway, was greatly downregulated in response to emodin injection (0.29-fold; [Figure 6(B)](#F0006){ref-type="fig"}; [Table 2](#t0002){ref-type="table"}). qPCR also confirmed the effect of emodin on the gene expressions. In addition, emodin increased the protein expression of p-AMPKα and p-YAP in the livers of mice as assessed by immunoblot analysis (data not shown). Thus, these data show that emodin triggers the induction of AMPK and Hippo signalling pathways.

![Activation of AMPK and YAP pathway by emodin in mouse liver. The heatmap depicts the changes in AMPK signalling pathway (A) and Hippo pathway signalling (B) related gene expression between control group and 10 mg/kg Emo-treated group using QuantSeq 3′ mRNA-Seq data. Red indicates higher gene expression values and blue indicates lower gene expression values. (C) Scheme of the mechanism. Emo: emodin.](IPHB_A_1750658_F0006_C){#F0006}

###### 

Regulated genes related to AMPK pathway emodin injected group compared to control group.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene symbol            Full name                                        Fold change                                                 Description                                                   
  ---------------------- ------------------------------------------------ ----------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------
  Up-regulated genes     Prkaa1                                           5′-AMP-activated protein kinase catalytic subunit alpha-1   1.246                                                         A regulator of cellular polarity by remodelling the actin\
                                                                                                                                                                                                    cytoskeleton

  Prkag2                 protein kinase, cGMP-dependent, type II          1.008                                                       A heterotrimeric protein composing AMP-activated\             
                                                                                                                                      protein kinase                                                

  Down-regulated genes   Prkaa2                                           5′-AMP-activated protein kinase catalytic subunit alpha-2   0.0803                                                        A catalytic subunit of the AMP-activated protein kinase

  Prkab1                 5′-AMP-activated protein kinase subunit beta-1   0.783                                                       A non-catalytic subunit of the AMP-activated protein kinase   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Regulated genes related to Hippo signalling pathway emodin injected group compared to control group.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene symbol            Full name                   Fold change              Description                                                                                                               
  ---------------------- --------------------------- ------------------------ ------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  Up-regulated genes     Tead4                       TEA Domain\              4.047                                                                                                                     Transcription factor which plays a key role in the Hippo signalling pathway
                                                     Transcription Factor 4                                                                                                                             

  Tead1                  TEA Domain\                 1.677                    Paralog of TEAD 4                                                                                                         
                         Transcription Factor 1                                                                                                                                                         

  Stk3                   Serine/Threonine Kinase 3   1.509                    Repress proliferation of mature hepatocytes                                                                               

  Mob1b                  MOB Kinase Activator 1B     1.356                    Binding with LATS1 and phosphorylates and inactivates YAP1                                                                

  Lats1                  Large Tumour\               1.151                    Inhibiting translocation into the nucleus of YAP1 by phosphorylation                                                      
                         Suppressor Kinase 1                                                                                                                                                            

  Down-regulated genes   Amotl1                      Angiomotin Like 1        0.790                                                                                                                     Encoding peripheral membrane protein that is a component of tight junctions

  Limd1                  LIM Domains\                0.761                    Involved in several cellular processes such as repression of gene transcription, cell differentiation and proliferation   
                         Containing 1                                                                                                                                                                   

  Wtip                   WT1 Interacting Protein     0.760                    Involved transcription\                                                                                                   
                                                                              corepressor activity                                                                                                      

  Fat4                   FAT Atypical Cadherin 4     0.340                    Plays a role in inhibition of YAP1-mediated neuroprogenitor cell proliferation and\                                       
                                                                              differentiation                                                                                                           

  Ajuba                  Ajuba LIM Protein           0.287                    Negatively regulates the Hippo signalling pathway and antagonises phosphorylation of YAP1                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion {#s0022}
==========

Oxidative stress causes cellular damage, aging and apoptosis and activates pro-inflammatory factors that induce inflammation (Varga et al. [@CIT0033]). Normally, ROS is generated during oxygen metabolism (Gupta et al. [@CIT0013]). In addition, ROS is considered as carcinogen because of its effects on mutagenesis, tumour promotion and progression (Waris and Ahsan [@CIT0036]). Therefore, the regulation of oxidative stress in tissue is an important strategy to prevent a line of disease. Here, we found that emodin had the ability to inhibit oxidative stress in hepatocytes stimulated with AA + iron as well as in mice injected with APAP. Moreover, we suggested the AMPK pathway as a mechanism of the effects of emodin.

Although acute pharmacological activation of AMPK was shown to decrease glutathione and facilitate oxidative stress, AMPK has been found to have beneficial functions in the cells including anti-oxidant, anti-tumour and anti-inflammation activities (Kim et al. [@CIT0015]; Shin and Kim [@CIT0031]). Oxidative stress causes binding of the mitochondrial protein to reactive metabolites, leading to mitochondrial dysfunction (McGill et al. [@CIT0022]). In our previous studies, some novel AMPK activators (e.g., isoliquiritigenin, isorhamnetin and sauchinone) were reported to attenuate AA and iron-induced oxidative stress via AMPK mediated signalling pathways (Kim et al. [@CIT0015]; Shin and Kim [@CIT0031]; Dong et al. [@CIT0008]).

Upon energy stress, the activation loop of α-subunit is exposed by conformational change, allowing it to be activated by phosphorylation of its upstream kinase, LKB1 (Choi et al. [@CIT0004]). Activated AMPK phosphorylates various target proteins (Shaw et al. [@CIT0030]). Though these signalling pathways, AMPK could protect mitochondria against oxidative damage (Wu and Wei [@CIT0037]). In this study, emodin significantly induced activation of AMPK and LKB1. Moreover, it had no protective effect under AMPK inhibition by compound C and LKB1 deficiency in Hela cells.

It has been reported that YAP1 protects cardiomyocytes against ROS-induced cell death and the reduced expression of YAP1 indicates the weak defence mechanism against oxidative stress (Del Re et al. [@CIT0006], Pan [@CIT0025]; Wu et al. [@CIT0038]; Shao et al. [@CIT0029]). Based on these reports, we investigated the effects of emodin on the Hippo pathway. Emodin markedly upregulated phosphorylation of YAP and LATS1. Considering this compound does not increase the phosphorylation of YAP in LKB1 deficient Hela cells, YAP inactivation by emodin might be related to the AMPK pathway.

We also performed quantitative RNA-seq analysis. With the advent and continuous refinement of NGS technology, total RNA-sequencing (RNA-seq) may be the most promising solution to identify changes in transcriptional machinery. However, this can likely be deleted (Wang et al. [@CIT0035]). In addition, RNA-seq has completely replaced microarray tools because it can accurately profile complete transcriptomes at cheaper rate and can be performed without exact knowledge of the genomic sequence in a species (Marioni et al. [@CIT0020]). To identify the target genes and the related pathways that might be responsible for the effects of emodin treatment, we conducted quantitative RNA-seq analysis of RNA samples extracted from both control and emodin treated mice liver tissues and found that strongly induced genes were related to the AMPK and the Hippo pathway.

APAP is an analgesic drug that is used worldwide. Treatment with APAP results in production of NAPQI, which is a well-known reactive metabolite of APAP, by liver cytochrome P450s (CYPs). Overdose of APAP lead to production of excessive amounts of NAPQI, which can cause hepatic GSH depletion and reduced redox capacity. These conditions can result in the accumulation oxidative stress in liver tissue (Truong et al. [@CIT0032]). Therefore, APAP is often used as a liver toxicity inducer in anti-oxidant and hepato-protective drug screening animal models (Lin et al. [@CIT0019]; Chen et al. [@CIT0002]; Olaleye et al. [@CIT0024]). In the present study, emodin successfully inhibited the elevation of plasma markers of hepatotoxicity and oxidative tissue damage in the liver induced by APAP. Because APAP also promotes extrahepatic damage, it is needed to determine to provide a more detailed analysis of the potential protective actions of emodin in the future.

Collectively, emodin attenuated oxidative damage in the hepatocyte cell line and in mice. In cells, emodin inhibited ROS generation and mitochondria damage induced by AA + iron was mediated via LKB1-AMPK and Hippo-YAP1 signals, which were also confirmed by NGS. In mice, emodin successfully decreased APAP-induced oxidative damage in the liver. Taken together, the results of this study suggest that emodin could be a potential hepatoprotectant as well as an antioxidant.
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